Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | MELK | Q14680 | 3/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17969256 | 0.99 | ITGB3 (0.54) | ITGB3ITGA2BF2PLGPLAU | |
| SCHEMBL17999901 | 0.91 | ITGB3 (0.53) | ITGB3ITGA2BF2PLGPLAU | |
| Hydrochloric Acid SCHEMBL17969235 | 0.90 | ITGB3 (0.55) | ITGB3ITGA2BF2PLGPLAU | |
| SCHEMBL16634809 | 0.89 | ITGB3 (0.49) | ITGB3ITGA2BF2PLGPLAU | |
| SCHEMBL17999902 | 0.88 | ITGB3 (0.48) | ITGB3ITGA2BF2PLGPLAU | |
| Hydrochloric Acid SCHEMBL17969248 | 0.88 | ITGB3 (0.51) | ITGB3ITGA2BF2PLGPLAU | |
| Hydrochloric Acid SCHEMBL17969234 | 0.87 | ITGB3 (0.50) | ITGB3ITGA2BF2PLGPLAU | |
| SCHEMBL7909620 | 0.84 | RAB9A (0.60) | ITGB3ITGA2BF2PLGPLAU | |
| SCHEMBL7903531 | 0.79 | F2 (0.56) | ITGB3ITGA2BF2PLGPLAU | |
| SCHEMBL12660516 | 0.79 | HDAC1 (0.59) | ITGB3ITGA2BF2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | ELI LILLY AND COMPANY | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229835-A1 | NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS | NAMPT, NAPRT, NNMT | ITGB3 3984/4885ITGA2B 3236/4885F2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.